Clinical Trial Update: REduction of Contrast Via DyeVert Used in CTO Procedures

View source ↗

Summary

A clinical trial evaluating DyeVert to reduce contrast use during chronic total occlusion procedures has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Total Occlusion of Coronary Artery

Drugs mentioned

• DyeVert

Snippet

Sponsor: Minneapolis Heart Institute Foundation | Conditions: Chronic Total Occlusion of Coronary Artery | Status: TERMINATED